Gilead/J&J Collaboration Seeks To Create Triple-Therapy Successor To Atripla
This article was originally published in The Pink Sheet Daily
Executive Summary
The opportunity for J&J's investigative non-nucleoside reverse transcriptase inhibitor may come at the expense of BMS, Gilead's partner on Atripla.
You may also be interested in...
Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
The four-drug combination pill for HIV has significant sales potential, and will be a mainstay for Gilead to protect its leadership in the market, but with two novel components there is still much work to be done.
Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
The four-drug combination pill for HIV has significant sales potential, and will be a mainstay for Gilead to protect its leadership in the market, but with two novel components there is still much work to be done.
Gilead's Positive Phase II Data On Quad Pill For HIV Eases Analysts Concerns
With two novel components included in Gilead's investigational four-drug, fixed-dose combination pill for HIV, the company has a full clinical program ahead of it - but the first Phase II results offer early signs of promise